JPMorgan Chase & Co. Raises Revvity (NYSE:RVTY) Price Target to $105.00

Revvity (NYSE:RVTY) had its price target increased by equities research analysts at JPMorgan Chase & Co. from $100.00 to $105.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 1.35% from the company’s previous close.

Several other research firms have also recently commented on RVTY. Weiss Ratings restated a “sell (d)” rating on shares of Revvity in a research report on Monday, December 29th. Jefferies Financial Group boosted their price objective on Revvity from $100.00 to $105.00 and gave the stock a “hold” rating in a research report on Monday. Robert W. Baird set a $129.00 target price on Revvity in a research report on Tuesday. TD Cowen reaffirmed a “hold” rating on shares of Revvity in a research note on Tuesday. Finally, Wells Fargo & Company boosted their price target on Revvity from $107.00 to $110.00 and gave the stock an “equal weight” rating in a research report on Tuesday. Five research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Revvity currently has a consensus rating of “Hold” and a consensus target price of $113.67.

Revvity Price Performance

Shares of NYSE RVTY opened at $103.60 on Tuesday. Revvity has a 1-year low of $81.36 and a 1-year high of $124.10. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.44. The business’s fifty day moving average price is $103.97 and its two-hundred day moving average price is $95.63. The firm has a market capitalization of $11.75 billion, a PE ratio of 49.81, a P/E/G ratio of 2.14 and a beta of 1.07.

Revvity (NYSE:RVTY) last announced its quarterly earnings results on Monday, February 2nd. The company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The company had revenue of $772.06 million during the quarter, compared to the consensus estimate of $759.81 million. During the same quarter in the previous year, the company posted $1.42 earnings per share. The company’s revenue for the quarter was up 5.9% compared to the same quarter last year. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, research analysts expect that Revvity will post 4.94 EPS for the current year.

Revvity declared that its board has initiated a share repurchase program on Monday, October 27th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the company to repurchase up to 8.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Hedge Funds Weigh In On Revvity

Several large investors have recently made changes to their positions in the business. Nicholas Company Inc. grew its stake in shares of Revvity by 8.1% in the 4th quarter. Nicholas Company Inc. now owns 143,330 shares of the company’s stock worth $13,867,000 after purchasing an additional 10,730 shares during the last quarter. Ethic Inc. boosted its holdings in Revvity by 15.6% during the fourth quarter. Ethic Inc. now owns 10,511 shares of the company’s stock worth $1,017,000 after buying an additional 1,420 shares in the last quarter. Sequoia Financial Advisors LLC boosted its holdings in Revvity by 11.4% during the fourth quarter. Sequoia Financial Advisors LLC now owns 36,359 shares of the company’s stock worth $3,518,000 after buying an additional 3,728 shares in the last quarter. Gateway Investment Advisers LLC grew its position in Revvity by 28.5% in the fourth quarter. Gateway Investment Advisers LLC now owns 4,596 shares of the company’s stock worth $445,000 after buying an additional 1,019 shares during the last quarter. Finally, Truist Financial Corp increased its holdings in shares of Revvity by 0.8% in the fourth quarter. Truist Financial Corp now owns 45,120 shares of the company’s stock valued at $4,365,000 after buying an additional 356 shares in the last quarter. Institutional investors own 86.65% of the company’s stock.

More Revvity News

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: TD Cowen raised its price target to $124 and kept a “buy” rating — a sizable ~20% upside vs. the recent price, signaling strong analyst conviction after the quarter. TD Cowen raise Benzinga
• Positive Sentiment: Wells Fargo lifted its target to $110 with an “equal weight” call, another upgrade that narrows downside risk. Wells Fargo raise
• Positive Sentiment: JPMorgan raised its target to $105 and maintained a “neutral” rating — a modest lift but further evidence of analyst re-rating after the results. JPMorgan raise
• Positive Sentiment: Revvity reported better-than-expected Q4 results and raised FY2026 guidance (EPS $5.35–5.45), which is the primary catalyst for upgrades and the improved momentum trade. Analysts boost forecasts
• Positive Sentiment: Zacks highlights Revvity as a strong momentum stock based on style scores, which can attract momentum-driven flows. Zacks momentum piece
• Neutral Sentiment: Investor commentary remains mixed; a Seeking Alpha piece calls Revvity “close to a buy” but cautious on valuation/risks, suggesting some analysts still see work to be done. Seeking Alpha
• Neutral Sentiment: Full earnings-call transcripts and deeper analyses (MSN/Yahoo) are available for investors wanting detail on segment performance, margin drivers, and guidance assumptions. MSN transcript Yahoo transcript
• Neutral Sentiment: A valuation-focused note examines recent share weakness vs. DCF gaps — useful for longer-term investors assessing whether upgraded targets leave room for upside. Yahoo valuation analysis

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.